Mergers

BRC Group reports 10.03% stake in Biomerica after private placement

BMRA

BRC Group Holdings, Inc. and B. Riley Principal Capital reported a Schedule 13D on Biomerica on August 28, 2026, showing 460,080 shares, or 10.03% of the class. The filing follows a private placement.

Investor Chat

Scorecard

BMRA
Investor Impact: 9/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-08
Very highHigh evidence
Investment Attractiveness: 4.7/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-08
Mixed

By the aibio.space news desk

The Raleigh, North Carolina skyline
The Raleigh, North Carolina skyline. Photo: Mark Turner, Public domain, via Wikimedia Commons. The picture shows the field, not the companies named.

BRC Group Holdings, Inc., B. Riley Principal Capital, LLC and Bryant R. Riley filed a Schedule 13D on August 28, 2026 on Biomerica, Inc. (Nasdaq: BMRA). The cover page lists 460,080 shares, or 10.03 percent of the class, for BRC Group Holdings and B. Riley Principal Capital. The percentage uses 4,588,968 shares outstanding as of August 20, 2026, as the issuer provided them. The filing follows a private placement that closed on August 26, 2026.

Why is this important: A Schedule 13D discloses a holder's stake and the plans or rights tied to it. Here the filing discloses a right to appoint a board representative, linked to the private placement. For holders, the question is how much influence a holder just above 10 percent will have on the board, and on any later sale of stock.

Bryant R. Riley is co-chief executive officer and chairman of the board of BRC Group Holdings, according to the filing. In our view, a 13D that gives a holder just above 10 percent a board designation right adds governance weight to a company that sold shares to its own directors and executive officers alongside B. Riley. The 13D and the 8-K describe that right in different terms, as set out below.

What the 13D says about the stake

The filing names three reporting persons: BRC Group Holdings, Inc., a Delaware corporation whose principal business is serving as a holding company; B. Riley Principal Capital, LLC, a Delaware limited liability company whose principal business is making investments; and Bryant R. Riley, an individual. The filing gives an aggregate purchase price of $736,128 for the 460,080 shares, paid from the working capital of B. Riley Principal Capital. It says the shares were bought for investment purposes and that the reporting persons may acquire more shares or dispose of some or all of theirs in the open market, through privately negotiated transactions or otherwise. They may also change their plans at any time.

Item 5 of the same filing gives 480,060 shares for each reporting person, also described as 10.03 percent of the class. The filing does not reconcile that count with the 460,080 shares on its cover page.

The private placement and the board right

The 13D says that, in connection with BRPC's purchase of shares, BRPC is entitled to appoint a representative to the issuer's board of directors, under the heading Private Placement, Board Representative. The Form 8-K filed August 26, 2026 describes the right with conditions. Its Securities Purchase Agreement, dated August 20, 2026, provides that while the B. Riley purchasers together own at least 10 percent of the voting power, B. Riley Principal Capital may designate one representative for election or appointment to the board, subject to Nasdaq Stock Market rules. The placement covered 1,393,705 shares at $1.60 a share, for approximately $2.23 million gross. Directors and certain executive officers must sign lock-up agreements for 180 days after the closing.

Background and what comes next

The Form 10-Q filed April 13, 2026 is the latest quarterly report before the 13D. It reported cash and cash equivalents of approximately $1,336,000 at February 28, 2026, and an accumulated deficit of approximately $55,798,000. It also says that factors raise substantial doubt about the company's ability to continue as a going concern. The 10-Q describes inFoods IBS as a test that uses a simple blood sample.

The 13D says that, at the closing, the issuer entered into an engagement letter with B. Riley Securities, Inc., an affiliate of BRC and B. Riley Principal Capital. The letter names that firm as exclusive financial advisor for the evaluation and potential pursuit of certain strategic transactions, with an initial term of 24 months. The 8-K says the company must file a registration statement for resale of the purchased shares within 30 calendar days of the Closing Date.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.